Bristol Myers Squibb (NYSE: BMY) has announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials, which assessed the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline…
ZOLL®, an Asahi Kasei company specializing in medical devices and software solutions, has announced the results of two significant studies on the economic burden of heart failure resulting from severe…
Castle Biosciences, Inc. (Nasdaq: CSTL) has announced new data highlighting a substantial reduction in healthcare management costs and an enhancement in the quality of life for patients with Barrett’s esophagus…
Next Health, recognized as a leader in proactive healthcare, has announced a significant expansion into the Sacramento area, Walnut Creek, and Reno through an area development agreement. This move aligns…
OS Therapies (NYSE-A: OSTX), a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates, has announced the appointments of Avril McKean Dieser, MA, JD, and Olivier R. Jarry, MS,…
Henry Schein Medical, part of Henry Schein, Inc. (Nasdaq: HSIC), is exhibiting at the EMS & FIRE PRO Expo from October 24-26, 2024. Located at booth #718, the exhibit features…
Siemens Healthineers is revolutionizing clinical lab automation by consolidating 25 tasks typically performed manually by staff, significantly reducing manual workflow steps by 75%. Traditional lab automation relies on a track…
The CVS Health® Foundation has announced a $1.5 million funding initiative to enhance access to healthcare services, medically tailored meals, and transportation for chronic disease patients in Atlanta. This funding…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company using its proprietary ARCUS® platform for advanced in vivo gene editing therapies, announced a poster presentation at the European Society…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) has voted to update the pneumococcal vaccination guidelines…
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced positive topline interim results from their ongoing Phase 3 clinical trial of sibeprenlimab for treating immunoglobulin A…
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced its financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Financial Highlights Year-to-Date 2024 Financial Overview Balance Sheet and…
